Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

By Z. Younossi, M. Stepanova, Nila Rafiq, H. Makhlouf, Zahra Younoszai, R. Agrawal, Z. Goodman. Hepatology, 2011

630 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0ece5da7c928e880042c765a22123a408c872c4c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Pathology and Forensic Medicine

Citations in the corpus

Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2015, background): “Unfortunately, studies on NASH confirmed by liver biopsy reported to date [9,10] included small number of patients, and used a definition of NASH that is different from currently accepted criteria [11,12] precluding meaningful conclusions [13,14].”
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, result): “Our results support data from previous studies, including our recent publication that used a smaller subset of this cohort [10], and other studies [13, 23], that primarily”
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up (2015, background): “The inability of the NAS to predict liver-related mortality has also been demonstrated by Younossi et al.15 in a recent study on 257 NAFLD patients.”
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “It is one of the main prognostic factors as the amount of fibrosis is correlated with the risk of developing cirrhosis and liver-related complications in viral and nonviral chronic liver diseases [1,2].”
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (2016, background): “Patients with steatosis, inflammation, ballooned hepatocytes, and pericellular/perisinusoidal fibrosis were classified as having NASH [30].”
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019, background): “Several studies investigated progression of NAFLD and its subtypes (4, 10-19).”
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (2016, methodology): “In addition, the presence of advanced fibrosis (stage 2) in NAFLD has been associated with increased liver-related mortality.((10,11)) These data, therefore, may be an indicator that grade of fibrosis is a surrogate for predicting liver-related mortality.”
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients (2012, background): “Experimental studies have shown that triglycerides themselves are not toxic and may in fact protect the liver from lipotoxicity by buffering the accumulation of fatty acids.29,30 Indeed, patients with rare genetic diseases display massive steatosis but will not develop inflammation or fibrosis, as i”
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016, background): “Steatohepatitis is indirectly associated with reduced hepatic survival in NAFLD.(5,23) It drives fibrogenesis, a slow process of hepatic scar formation that can result in cirrhosis and its deadly complications, such as liver failure, portal hypertension, and hepatocellular”